NWCJvdD has received research support from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, Cellectis, and BMS, and serves in advisory boards for Janssen Pharmaceuticals, Amgen, Celgene, BMS, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Galapagos, Kite Pharma, Merck, Pfizer, AbbVie, and Servier, all paid to his institution. CFdL has served in advisory boards for J&J, BMS, Amgen, Pfizer, Sanofi, Beigene, GSK, Roche, and Menarini; has received honoraria from Amgen, J&J, BMS, GSK, Sanofi, Pfizer, Beigene; has received research support from BMS, J&J, Amgen, GSK; and is the principal investigator on trials evaluating the role of cesnicabtagene autoleucel (ARI0002 cells) in patients with multiple myeloma.